# Clock Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clock-bio

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.clock.bio/
- Total disclosed funding: $5.3M
- Latest round: Seed (Apr 30, 2024)
- Investors on record: 3

## About

Based in Cambridge, UK, and founded in 2020, Clock Bio Limited focuses on research on regenerative drugs based on pluripotent stem cells to prevent and treat age-related illnesses. As of 2023, the company is headed by its CEO Markus Gstöttner. In August 2023, the firm raised USD 4 million in venture funding from investor BlueYard Capital. In October 2024,  Clock Bio Ltd raised USD 5.3 million in seed funding led by LocalGlobe, with participation from BlueYard Capital and Onsight Ventures.

The company has created a force-aging model that ages hiPSCs and activates their self-rejuvenation system. Large samples of these cells were subjected to CRISPR screening, which made it possible to find gene candidates that are causally important for cell rejuvenation. This makes it possible to fully decode the biology of rejuvenation and the associated IP. Innovative therapeutic strategies are developed using this knowledge.

The company plans to use the August 2023 funding to decode all rejuvenation programs in human cells and to create an atlas of disease and rejuvenation targets for clinical translation.

## Funding rounds

- Seed, Apr 30, 2024, $5.3M — BlueYard Capital, LocalGlobe, Onsight Ventures

## Investors

- BlueYard Capital (https://capitalatlas.ai/funds/blueyard-capital) — Seed
- LocalGlobe (https://capitalatlas.ai/funds/localglobe) — Seed
- Onsight Ventures (https://capitalatlas.ai/funds/onsight-ventures) — Seed